Risk factors for non-responsiveness to 5-aminosalicylic acid in patients with ulcerative colitis identified using retrospective clinical study and Mendelian randomization

被引:0
作者
Ye, Zhi-Ning [1 ,2 ]
Liu, Xin-Tian [1 ,2 ]
Gu, Yue-Ming [1 ,2 ]
Mao, Shu-Xian [3 ,4 ]
Liang, Dan-Hong [1 ,2 ]
Zhan, Kai [1 ,2 ]
Lei, Hao-Qiang [5 ]
Huang, Shao-Gang [3 ,4 ]
机构
[1] Guangzhou Univ Chinese Med, Affiliated Dongguan Hosp, Dongguan, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Coll 9, Dongguan, Peoples R China
[3] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Gastroenterol, 16 Airport Rd, Guangzhou 510120, Peoples R China
[4] Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China
[5] Huangpu Peoples Hosp Zhongshan, Zhongshan, Peoples R China
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
基金
中国国家自然科学基金;
关键词
Ulcerative colitis; 5-Aminosalicylic acid; Responsiveness; Allergy; Aspartate aminotransferase-to-alanine aminotransferase ratio; Inhibitor of nuclear factor kappa-B kinase subunit alpha; INFLAMMATORY-BOWEL-DISEASE; MESALAZINE; POLYMORPHISMS; ASSOCIATION;
D O I
10.1038/s41598-025-89620-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This study aimed to identify risk factors and potential targets associated with non-responsiveness to 5-Aminosalicylic acid (5-ASA) in patients with ulcerative colitis (UC). Patients with mild to moderate UC were grouped based on their responsiveness to 5-ASA. Regression analysis was conducted to identify risk factors for non-responsiveness, while Mendelian randomization (MR) analysis was used to evaluate the potential targets. Among 50 patients (11 non-responders and 39 responders), non-responders exhibited higher incidences of fever, back pain, allergy history, and ankylosing spondylitis, as well as elevated monocyte count and alanine aminotransferase (ALT) level, but a lower aspartate aminotransferase-to-ALT (AST/ALT) ratio (all P < 0.05). Allergy history was a risk factor (OR 140.50, P = 0.021), while a high AST/ALT ratio was a protective factor (OR 0.001, P = 0.023) for non-responsiveness. The area under the receiver operating characteristic curve for the AST/ALT ratio was 0.80. MR analysis showed that inhibition of the inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) by 5-ASA, targeting ALT, increased the risk of UC (OR 1.02, P = 0.002). Our findings suggested that allergy history and the AST/ALT ratio were associated with non-responsiveness to 5-ASA, and CHUK was identified as a potential target for ALT-related non-responsiveness.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database
    Ota, Takumi
    Takebe, Takahiro
    Shimizu, Yutaka
    Orido, Takashi
    Tanaka, Hiroyuki
    Nakamura, Shiro
    DIGESTION, 2024, 105 (03) : 232 - 242
  • [22] Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis
    Olaisen, Maya
    Spigset, Olav
    Flatberg, Arnar
    Granlund, Atle van Beelen
    Brede, Wenche Rodseth
    Albrektsen, Grethe
    Royset, Elin Synnove
    Gilde, Bodil
    Sandvik, Arne Kristian
    Martinsen, Tom Christian
    Fossmark, Reidar
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (10) : 1301 - 1313
  • [23] Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission
    Ewe, K
    Becker, K
    Ueberschaer, B
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1996, 34 (04): : 225 - 229
  • [24] Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis
    Frieri, G
    Giacomelli, R
    Pimpo, M
    Palumbo, G
    Passacantando, A
    Pantaleoni, G
    Caprilli, R
    GUT, 2000, 47 (03) : 410 - 414
  • [25] An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements
    Moshkovska, T.
    Stone, M. A.
    Clatworthy, J.
    Smith, R. M.
    Bankart, J.
    Baker, R.
    Wang, J.
    Horne, R.
    Mayberry, J. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (11-12) : 1118 - 1127
  • [26] Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
    Shehab, Mohammad
    Alrashed, Fatema
    Alyaseen, Munerah
    Safar, Zainab
    Adekunle, Tunrayo
    Alfadhli, Ahmad
    Bessissow, Talat
    VACCINES, 2024, 12 (04)
  • [27] Questionnaire survey to identify meal habits which influence adherence to oral 5-aminosalicylic acid regimens in patients with ulcerative colitis
    Suzuki, Keiko
    Fujii, Hironori
    Yamauchi, Tomoyo
    Kato-Hayashi, Hiroko
    Ishihara, Masashi
    Iihara, Hirotoshi
    Hirose, Chiemi
    Nishida, Shohei
    Funato, Miyui
    Kobayashi, Ryo
    Yasuda, Koji
    Ino, Yoko
    Tamaki, Hirofumi
    Yamashita, Shuji
    Iguchi, Kazuhiro
    Noguchi, Yoshihiro
    Teramachi, Hitomi
    Takada, Jun
    Kubota, Masaya
    Ibuka, Takashi
    Araki, Hiroshi
    Shimizu, Masahito
    Suzuki, Akio
    JOURNAL OF PHARMACY PRACTICE AND RESEARCH, 2021, 51 (05) : 374 - 380
  • [28] Efficacy of single vs multiple doses of 5-aminosalicylic acid (5-ASA) in the treatment of mild-moderate ulcerative colitis: an open randomized clinical trial
    Wang, Junshan
    Shi, Yanhong
    Liu, Zhanju
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21654 - 21662
  • [29] Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
    Higgins, P. D. R.
    Rubin, D. T.
    Kaulback, K.
    Schoenfield, P. S.
    Kane, S. V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 247 - 257
  • [30] Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis
    Yamamoto, Yuki
    Masuda, Satohiro
    Nakase, Hiroshi
    Matsuura, Minoru
    Maruyama, Shihoko
    Hisamatsu, Tadakazu
    Suzuki, Yasuo
    Matsubara, Kazuo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2019, 42 (01) : 81 - 86